Literature DB >> 20708856

Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning.

Nils D Arvold1, Andrzej Niemierko, Harvey J Mamon, Carlos Fernandez-del Castillo, Theodore S Hong.   

Abstract

PURPOSE: Pancreatic cancer primary tumor size measurements are often discordant between computed tomography (CT) and pathologic specimen after resection. Dimensions of the primary tumor are increasingly relevant in an era of highly conformal radiotherapy. METHODS AND MATERIALS: We retrospectively evaluated 97 consecutive patients with resected pancreatic cancer at two Boston hospitals. All patients had CT scans before surgical resection. Primary endpoints were maximum dimension (in millimeters) of the primary tumor in any direction as reported by the radiologist on CT and by the pathologist for the resected gross fresh specimen. Endoscopic ultrasound (EUS) findings were analyzed if available.
RESULTS: Of the patients, 87 (90%) had preoperative CT scans available for review and 46 (47%) had EUS. Among proximal tumors (n = 69), 40 (58%) had pathologic duodenal invasion, which was seen on CT in only 3 cases. The pathologic tumor size was a median of 7 mm larger compared with CT size for the same patient (range, -15 to 43 mm; p < 0.0001), with 73 patients (84%) having a primary tumor larger on pathology than CT. Endoscopic ultrasound was somewhat more accurate, with pathologic tumor size being a median of only 5 mm larger compared with EUS size (range, -15 to 35 mm; p = 0.0003).
CONCLUSIONS: Computed tomography scans significantly under-represent pancreatic cancer tumor size compared with pathologic specimens in resectable cases. We propose a clinical target volume expansion formula for the primary tumor based on our data. The high rate of pathologic duodenal invasion suggests a risk of duodenal under-coverage with highly conformal radiotherapy.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20708856      PMCID: PMC4362517          DOI: 10.1016/j.ijrobp.2010.04.058

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  28 in total

1.  Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma.

Authors:  Morten Hoyer; Henrik Roed; Lisa Sengelov; Anders Traberg; Lars Ohlhuis; Jorgen Pedersen; Hanne Nellemann; Anne Kiil Berthelsen; Frey Eberholst; Svend Aage Engelholm; Hans von der Maase
Journal:  Radiother Oncol       Date:  2005-07       Impact factor: 6.280

2.  Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography.

Authors:  P Legmann; O Vignaux; B Dousset; A J Baraza; L Palazzo; I Dumontier; J Coste; A Louvel; G Roseau; D Couturier; A Bonnin
Journal:  AJR Am J Roentgenol       Date:  1998-05       Impact factor: 3.959

3.  Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer.

Authors:  Hiroyuki Shinchi; Sonshin Takao; Hidetoshi Noma; Yoichiro Matsuo; Yuko Mataki; Shinichiro Mori; Takashi Aikou
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-05-01       Impact factor: 7.038

4.  Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.

Authors:  Albert C Koong; Erin Christofferson; Quynh-Thu Le; Karyn A Goodman; Anthony Ho; Timothy Kuo; James M Ford; George A Fisher; Ralph Greco; Jeffrey Norton; George P Yang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-01       Impact factor: 7.038

5.  Pancreatic-phase versus portal vein-phase helical CT of the pancreas: optimal temporal window for evaluation of pancreatic adenocarcinoma.

Authors:  G W Boland; M E O'Malley; M Saez; C Fernandez-del-Castillo; A L Warshaw; P R Mueller
Journal:  AJR Am J Roentgenol       Date:  1999-03       Impact factor: 3.959

6.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

Authors:  Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

7.  Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.

Authors:  Edgar Ben-Josef; Anthony F Shields; Ulka Vaishampayan; Vainutis Vaitkevicius; Basil F El-Rayes; Patrick McDermott; Jay Burmeister; Todd Bossenberger; Philip A Philip
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

8.  Pancreatic tumor motion on a single planning 4D-CT does not correlate with intrafraction tumor motion during treatment.

Authors:  A Yuriko Minn; Devin Schellenberg; Peter Maxim; Yelin Suh; Stephen McKenna; Brett Cox; Sonja Dieterich; Lei Xing; Edward Graves; Karyn A Goodman; Daniel Chang; Albert C Koong
Journal:  Am J Clin Oncol       Date:  2009-08       Impact factor: 2.339

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

10.  Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer.

Authors:  John DeWitt; Benedict Devereaux; Melissa Chriswell; Kathleen McGreevy; Thomas Howard; Thomas F Imperiale; Donato Ciaccia; Kathleen A Lane; Dean Maglinte; Kenyon Kopecky; Julia LeBlanc; Lee McHenry; James Madura; Alex Aisen; Harvey Cramer; Oscar Cummings; Stuart Sherman
Journal:  Ann Intern Med       Date:  2004-11-16       Impact factor: 25.391

View more
  21 in total

1.  Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer.

Authors:  Charles C Hsu; Christopher L Wolfgang; Daniel A Laheru; Timothy M Pawlik; Michael J Swartz; Jordan M Winter; Raymond Robinson; Barish H Edil; Amol K Narang; Michael A Choti; Ralph H Hruban; John L Cameron; Richard D Schulick; Joseph M Herman
Journal:  J Gastrointest Surg       Date:  2012-02-07       Impact factor: 3.452

2.  External assessment of the Early Mortality Risk Score in patients with adenocarcinoma undergoing pancreaticoduodenectomy.

Authors:  Gaëtan-Romain Joliat; David Petermann; Nicolas Demartines; Markus Schäfer
Journal:  HPB (Oxford)       Date:  2015-04-23       Impact factor: 3.647

Review 3.  Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.

Authors:  Matthew H G Katz; Robert Marsh; Joseph M Herman; Qian Shi; Eric Collison; Alan P Venook; Hedy L Kindler; Steven R Alberts; Philip Philip; Andrew M Lowy; Peter W T Pisters; Mitchell C Posner; Jordan D Berlin; Syed A Ahmad
Journal:  Ann Surg Oncol       Date:  2013-02-23       Impact factor: 5.344

4.  Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies.

Authors:  Hiroshi Haeno; Mithat Gonen; Meghan B Davis; Joseph M Herman; Christine A Iacobuzio-Donahue; Franziska Michor
Journal:  Cell       Date:  2012-01-20       Impact factor: 41.582

Review 5.  Resectable, borderline resectable, and locally advanced pancreatic cancer: what does it matter?

Authors:  Daniel M Halperin; Gauri R Varadhachary
Journal:  Curr Oncol Rep       Date:  2014-02       Impact factor: 5.075

6.  Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study.

Authors:  Agata I Rembielak; Pooja Jain; Andrew S Jackson; Melanie M Green; Gillian R Santorelli; Gillian A Whitfield; Adrian Crellin; Angel Garcia-Alonso; Ganesh Radhakrishna; James Cullen; M Ben Taylor; Ric Swindell; Catharine M West; Juan Valle; Azeem Saleem; Patricia M Price
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

7.  The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma.

Authors:  William A Hall; Lauren E Colbert; Dana Nickleach; Jeffrey Switchenko; Yuan Liu; Theresa Gillespie; Joseph Lipscomb; Claire Hardy; David A Kooby; Roshan S Prabhu; John Kauh; Jerome C Landry
Journal:  J Gastrointest Oncol       Date:  2014-04

8.  Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: implications for radiation therapy planning.

Authors:  Haoming Qiu; Aaron T Wild; Hao Wang; Elliot K Fishman; Ralph H Hruban; Daniel A Laheru; Rachit Kumar; Amy Hacker-Prietz; Richard Tuli; Erik Tryggestad; Richard D Schulick; John L Cameron; Barish H Edil; Timothy M Pawlik; Christopher L Wolfgang; Joseph M Herman
Journal:  Radiother Oncol       Date:  2012-08-08       Impact factor: 6.280

9.  Comparison of imaging modalities for measuring the diameter of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Tri Huynh; Karla Ali; Shraddha Vyas; Kaleena Dezsi; Destiny Strickland; Toni Basinski; Dung-Tsa Chen; Kun Jiang; Barbara Centeno; Mokenge Malafa; Jason B Klapman; Pamela J Hodul; Daniel Jeong; Jennifer B Permuth
Journal:  Pancreatology       Date:  2020-02-21       Impact factor: 3.996

10.  Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery.

Authors:  Shannan M Dickinson; Caitlin A McIntyre; Juliana B Schilsky; Kate A Harrington; Scott R Gerst; Jessica R Flynn; Mithat Gonen; Marinela Capanu; Winston Wong; Sharon Lawrence; Peter J Allen; Eileen M O'Reilly; William R Jarnagin; Michael I D'Angelica; Vinod P Balachandran; Jeffrey A Drebin; T Peter Kingham; Amber L Simpson; Richard K Do
Journal:  Abdom Radiol (NY)       Date:  2020-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.